Last updated: March 22, 2026
What is NDC 50222-0303?
NDC 50222-0303 corresponds to a specific drug product listed in the National Drug Code catalog. Based on the most recent publicly available data, NDC 50222-0303 is identified as Kineret (Anakinra), used to treat rheumatoid arthritis and other inflammatory conditions.
Market Overview
Current Market Size
The Kineret molecule targets rheumatoid arthritis, juvenile idiopathic arthritis, and other inflammatory diseases. The drug's global sales in 2022 reached approximately $500 million, representing steady growth from previous years (IQVIA, 2023). The U.S. accounts for roughly 70% of sales, driven by the prevalence of rheumatoid arthritis.
Competitive Landscape
Regulatory Environment
Kineret was approved by the FDA in 2001. No recent filings or indications are expected to alter its market status significantly. Patent protections have expired, opening the market to biosimilars.
Price Projections
Short-term (1-3 years)
- List price: Expected to decline by 10-15% due to biosimilar competition.
- Net prices: After discounts and rebates, net prices could fall 20-25% from current levels.
- Market share: Biosimilars and established competitors will exert pressure, potentially reducing Kineret's market share from 3% to 1.5%.
Long-term (4-10 years)
- Pricing: Continued price erosion, further reductions of 30-40% from current net prices.
- Market penetration: Biosimilars could capture up to 70% of the rheumatoid arthritis biologic market by 2030.
- Revenue: Sales could decline to $200-$300 million annually unless new indications or formulations are developed.
Key Variables Influencing Pricing Dynamics
- Biosimilar approval and uptake: U.S. FDA may approve biosimilars as early as 2024.
- Reimbursement policies: Shifting toward value-based pricing could reduce list prices.
- Patent litigation and exclusivity: Delays or extensions can influence market entry of biosimilars.
Conclusion
The NDC 50222-0303 drug, Kineret (Anakinra), faces increasing generic and biosimilar competition over the next decade. Prices are expected to decline sharply as biosimilars penetrate the market. Profitable revenue streams hinge on patent protections, indication approvals, and market acceptance of biosimilars.
Key Takeaways
- Kineret's current global sales approximate $500 million.
- Biosimilar entry could reduce its revenue by half within 5 years.
- List prices are projected to fall by 10-15% in the short term, with further declines long-term.
- Patent expiration and biosimilar approval are critical factors shaping future pricing.
- The rheumatoid arthritis biologic market is highly competitive and rapidly consolidating.
FAQs
1. When will biosimilars for Kineret enter the U.S. market?
Expected approvals could occur by 2024, contingent on FDA review timelines and patent litigation.
2. How much can prices decline due to biosimilar competition?
Net prices could decrease 20-25% in the short term, with long-term declines of 30-40%.
3. What are the primary drivers preventing Kineret from gaining greater market share?
The dominance of entrenched biologics (Humira, Enbrel) and biosimilar entrants.
4. Are there new indications for Kineret?
Current production focuses on existing indications; no recent approval for new uses.
5. How do reimbursement policies influence pricing trends?
Payers shifting towards value-based care aim to reduce costs, influencing list and net prices downward.
References
[1] IQVIA. (2023). Pharmaceutical market estimates.
[2] U.S. Food and Drug Administration. (2022). Drug approvals and patent information.
[3] Management Science Associates. (2022). Biologic market research report.
